(261 days)
Not Found (Predicate device is identified but no K/DEN number is provided in the document)
Not Found
No
The summary describes a standard enzyme immunoassay (EIA) for detecting antibodies. There is no mention of AI, ML, or any computational methods that would suggest their use in the device's operation or interpretation. The performance studies are based on direct comparison to a predicate device and standard statistical metrics.
No.
The device is for in vitro diagnostic use, specifically for detecting antibodies to aid in differentiating active/recent infection from past infection, not for treating a condition.
Yes
The first point under "Intended Use / Indications for Use" explicitly states: "1. For in vitro diagnostic use only."
No
The device description clearly states it is a solid-phase enzyme immunoassay (EIA) performed in microwells, indicating a physical kit with reagents and a testing procedure, not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Explicit Statement: The very first point under "Intended Use / Indications for Use" is "For in vitro diagnostic use only." This is a clear and direct statement of its intended purpose.
- Nature of the Test: The device performs a test on human serum (a biological sample taken from the body) to detect antibodies. This is a classic example of an in vitro diagnostic test, as it's performed outside of the living organism.
- Purpose of the Test: The test is used as an "aid in differentiating active or recent infection, from past infection." This indicates that the results are intended to provide information for a medical diagnosis or to aid in making a clinical decision.
The other sections of the document further support this:
- Device Description: Describes a "solid-phase enzyme immunoassay (EIA)" performed in microwells, which is a common method for in vitro diagnostic tests.
- Intended User / Care Setting: While it mentions manual use or use with a specific system, the overall context is for diagnostic use.
- Performance Studies and Key Metrics: The inclusion of clinical testing data, sensitivity, specificity, and overall agreement are all standard elements of documentation for an IVD device, demonstrating its performance in a diagnostic context.
- Predicate Device: The comparison to another EBV IgG ELISA test (Gull Laboratories') further confirms its place within the realm of in vitro diagnostics.
Therefore, based on the provided information, the SeraQuest EB VCA IgG test is clearly an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The EB VCA IgG test is intended for the qualitive and semi-quantative detection of IgG antibodies which are directed against Epstein-Barr virus capsid antigen. It has been developed to be used as an aid in differentiating active or recent Epstein-Barr virus infection from past infection. For manual use, or for use with the HyPrep System Plus. For In Vitro Diagnostic Use Only.
-
- For in vitro diagnostic use only.
-
- For the qualitative and semi-quantitative detection of IgG antibodies to Epstein-Barr viral capsid antigen (VCA) in human serum by enzyme immunoassay.
-
- For use as an aid in differentiating active or recent infection, from past infection.
-
- For manual use, or for use with the HyPrep System Plus semi-automated fluid handler.
Product codes (comma separated list FDA assigned to the subject device)
LSE
Device Description
The SeraQuest EB VCA IgG test is a solid-phase enzyme immunoassay (EIA), which is performed in microwells, at room temperature, in three thity minute incubations. It has been developed in IgG antibodies which are directed against Enotein Romains. It has been develope look to the superialism (in throe thirty minute incubations. It nas been developed to
The Calibrators in the SeraQuest EB VCA IgG test set have been assigned Index values based on an in-house standard. Test results are reported as Index values.
Principle:
Diluted samples are incubated in wells coated with Epstein-Barr virus capsid antigen. Antibodies directed against Epstein-Barr virus capsid antigen (if present) are immobilized in the wells. Residual sample is eliminated by washing and draining and online in the well. Hesidual human IgG) is added and including to Epstein-Barr virus capsid antibodies to human IgG) is added and incubated. If IgG anibodies to Epstein-Barry present, the conjugate will be immobilized in the wells. Residual conjugate is eliminated by washing and draining, and the enzyme substrate is added and incubated. In the presence of the the substrate is converted to onlymo oubstrate is added and incubation. In the presence of the substrate
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Of the 157 specimens tested, 130 were positive, and 9 were negative in both the SeraQuest and Of the 157 specimens tested, 130 were positive in of remains and the many of in Gull Laboratories tests (please see Table by the SeraQuest test, and 11 specimens which were was negative by the Gull test, was postive by the SeraQuest test. Six specimens gave equivocal results positive by the Gull test, were negative by the SeraQuest test. Six spe positive by the Gulf test, were nogalive by the been see Table 1 below.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Summary of Clinical Testing:
Of the 157 specimens tested, 130 were positive, and 9 were negative in both the SeraQuest and Of the 157 specimens tested, 130 were positive in of remains and the many of in Gull Laboratories tests (please see Table by the SeraQuest test, and 11 specimens which were was negative by the Gull test, was postive by the SeraQuest test. Six specimens gave equivocal results positive by the Gull test, were negative by the SeraQuest test. Six spe positive by the Gulf test, were nogalive by the been see Table 1 below.
TABLE 1.
.ESULTS OF SeraQuest EB VCA IgG ASSAYS, AND GULL VCA IgG ASSAYS, OF .ESULTS OF Seraudes EB VCA Titles TESTS WERE PERFORMED IN-HOUSE AT QUEST INTERNATIONAL, INC., MIAMI, FL.
| GULL
VCA
| IgG | SeraQuest EB VCA IgG | |||||
|---|---|---|---|---|---|---|
| Positive | Equivocal | Negative | % | 95 % CI | ||
| Positive | 130 | 2 | 11 | Relative sensitivity* | 92.2 | 87.8 to 96.6 |
| Equivocal | 2 | 1 | 0 | Relative specificity* | 90.0 | 71.4 to 100 |
| Negative | 1 | 1 | 9 | Overall agreement* | 92.1 | 87.7 to 96.4 |
- Excluding equivocal results.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Relative sensitivity*: 92.2 (95 % CI: 87.8 to 96.6)
Relative specificity*: 90.0 (95 % CI: 71.4 to 100)
Overall agreement*: 92.1 (95 % CI: 87.7 to 96.4)
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Not Found (Predicate device is identified but no K/DEN number is provided in the document)
The SeraQuest EB VCA IgG test is substantially equivalent in intended use and performance, to the Gull Laboratories' EBV IgG ELISA test, Gull Laboratories, Inc., Salt Lake City, Utah.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.3235 Epstein-Barr virus serological reagents.
(a)
Identification. Epstein-Barr virus serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to Epstein-Barr virus in serum. The identification aids in the diagnosis of Epstein-Barr virus infections and provides epidemiological information on diseases caused by these viruses. Epstein-Barr viruses are thought to cause infectious mononucleosis and have been associated with Burkitt's lymphoma (a tumor of the jaw in African children and young adults) and postnasal carcinoma (cancer).(b)
Classification. Class I (general controls).
0
OCT 2 8 1999
APPENDIX 3.
Quest International, Inc., 1938 N.E. 148th Terrace, N. Miami, FL 33181 Page No. GAL
510(k) SUMMARY
| Applicant: | Quest International, Inc.
1938 N.E. 148th Terrace
North Miami, FL 33181 |
|------------------------|-------------------------------------------------------------------------------|
| Registration No. | 1061839 |
| Contact Person: | Robert A. Cort, V.P., Quality Assurance |
| Telephone: | (305) 948-8788 |
| Telefax: | (305) 948-4876 |
| Manufacturing Site: | Same as above |
| Device: | SeraQuest® EB VCA IgG |
| Device Name: | Epstein-Barr virus serological reagents (21CFR § 866.3235) |
| Device Classification: | Class I (general controls) |
ascription:
The SeraQuest EB VCA IgG test is a solid-phase enzyme immunoassay (EIA), which is performed in microwells, at room temperature, in three thity minute incubations. It has been developed in
IgG antibodies which are directed against Enotein Romains. It has been develope look to the superialism (in throe thirty minute incubations. It nas been developed to
The Calibrators in the SeraQuest EB VCA IgG test set have been assigned Index values based on an in-house standard. Test results are reported as Index values.
Principle:
Diluted samples are incubated in wells coated with Epstein-Barr virus capsid antigen. Antibodies directed against Epstein-Barr virus capsid antigen (if present) are immobilized in the wells. Residual sample is eliminated by washing and draining and online in the well. Hesidual human IgG) is added and including to Epstein-Barr virus capsid antibodies to
human IgG) is added and incubated. If IgG anibodies to Epstein-Barry present, the conjugate will be immobilized in the wells. Residual conjugate is eliminated by washing and draining, and the enzyme substrate is added and incubated. In the presence of the the substrate is converted to onlymo oubstrate is added and incubation. In the presence of the substrate
Intended Use:
tended Use: The EB VCA IgG test is intended for the qualitive and semi-quantative detection of in of the collection of or rigated in ine qualified and semi-quantative defection of any
1
munoassay, as an aid in differentiating active or recent Epstein-Barr virus infection from past nfection. For manual use, or for use with the HyPrep System Plus. For In Vitro Diagnostic Use Only.
Predicate Device:
The SeraQuest EB VCA IgG test is substantially equivalent in intended use and performance, to the Gull Laboratories' EBV IgG ELISA test, Gull Laboratories, Inc., Salt Lake City, Utah.
Summary of technological characteristics:
| Characteristic | SeraQuest EB VCA IgG | Gull Laboratories ' EBV IgG ELISA |
|---|---|---|
| Description: | Enzyme Immunoassay | Enzyme Immunoassay |
| Intended Use: | The detection of IgG | |
| antibodies against Epstein- | ||
| Barr virus capsid antigen | ||
| in human serum. | The detection of IgG | |
| antibodies against Epstein- | ||
| Barr virus capsid antigen | ||
| in human serum. | ||
| Solid Phase: | Plastic Microwell | Plastic Microwell |
| ntigen : | Recombinant p18 | Purified gp 125 |
| Number of Incubation Periods: | Three | Three |
| Sample Dilution: | 1:50 | 1:21 |
| Sample Incubation | ||
| Duration: | 30 minutes | 30 minutes |
| Incubation Temperature: | Room temperature | 37 °C. |
| Ezyme-labeled Conjugate: | ||
| Antibody | Goat anti-human IgG | Goat anti-human IgG |
| Enzyme | Alkaline phosphatase | Alkaline phosphatase |
| Conjugate Volume: | 100 ul | 100 ul |
| Conjugate Incubation | ||
| Duration: | 30 minutes | 30 minutes |
| Substrate: | p-Nitrophenyl | |
| phosphate | p-Nitrophenyl | |
| phosphate |
2
| APPENDIX 3. | Quest International, Inc., 1938 N.E. 148th Terrace, N. Miami, FL 33181
Page No. 86 | |
|-----------------------------------|---------------------------------------------------------------------------------------|------------------------------|
| ubtrate Volume: | 100 μl | 100 μl |
| Substrate Incubation
Duration: | 30 minutes | 30 minutes |
| Stop Reagent: | 0.5 M Trisodium
phosphate | 1.5 N Sodium
hydroxide |
| Stop Reagent Volume: | 100 μl | 100 μl |
| Readout: | Spectrophotometric
405 nm | Spectrophotometric
405 nm |
Summary of Clinical Testing:
Of the 157 specimens tested, 130 were positive, and 9 were negative in both the SeraQuest and Of the 157 specimens tested, 130 were positive in of remains and the many of in Gull Laboratories tests (please see Table by the SeraQuest test, and 11 specimens which were was negative by the Gull test, was postive by the SeraQuest test. Six specimens gave equivocal results
positive by the Gull test, were negative by the SeraQuest test. Six spe positive by the Gulf test, were nogalive by the been see Table 1 below.
TABLE 1.
.ESULTS OF SeraQuest EB VCA IgG ASSAYS, AND GULL VCA IgG ASSAYS, OF .ESULTS OF Seraudes EB VCA Titles TESTS WERE PERFORMED IN-HOUSE AT QUEST INTERNATIONAL, INC., MIAMI, FL.
| GULL
VCA
| IgG | SeraQuest EB VCA IgG | |||||
|---|---|---|---|---|---|---|
| Positive | Equivocal | Negative | % | 95 % CI | ||
| Positive | 130 | 2 | 11 | Relative sensitivity* | 92.2 | 87.8 to 96.6 |
| Equivocal | 2 | 1 | 0 | Relative specificity* | 90.0 | 71.4 to 100 |
| Negative | 1 | 1 | 9 | Overall agreement* | 92.1 | 87.7 to 96.4 |
- Excluding equivocal results.
V Calculated by the normal method.
Reference: Gardner, M.J. and Altman, D.G., Confidence Intervals Rather Than Hypothesis Testing. Brit. Med. J., 292: 746-750, 1986.
3
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle or bird symbol with three curved lines representing its wings or body. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular pattern around the bird symbol.
OCT 2 8 1999
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Mr. Robert A. Cort Vice President, Quality Assurance Quest International, Inc. 1938 N.E. 148th Terrace North Miami, Florida 33181
Re: K990410 Trade Name: SeraQuest EB VCA IgG Regulatory Class: I Product Codc: LSE Dated: August 12, 1999 Received: September 8, 1999
Dear Mr. Cort:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment datc of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice rcquirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Eederal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
4
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"
Sincerely yours,
Steven Autman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Quest International, Inc., 1938 N.E. 148th Terrace, N. Miami, FL 33181 Page No. (UC
APPENDIX 6
Page 1 of 1
510(k) Number (if known): ________
Device Name: SeraQuest EB VCA IgG
Indications For Use:
-
- For in vitro diagnostic use only.
-
- For the qualitative and semi-quantitative detection of IgG antibodies to Epstein-Barr viral capsid antigen (VCA) in human serum by enzyme immunoassay.
-
- For use as an aid in differentiating active or recent infection, from past infection.
-
- For manual use, or for use with the HyPrep System Plus semi-automated fluid handler.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Woody Dubois
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K990410
Prescription Use (Per 21 CFR 801.109)
OR
Over-The-Counter Use__________________________________________________________________________________________________________________________________________________________
(Optional Format 1-2-96)